A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GE Healthcare
ClinicalTrials.gov Identifier:
NCT00565721
First received: November 28, 2007
Last updated: August 13, 2014
Last verified: August 2014

November 28, 2007
August 13, 2014
November 2007
October 2011   (final data collection date for primary outcome measure)
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]

    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. 0.22 and 0.24 equals a weak positive correlation and 0.16 and 0.18 equals a negligible correlation.

    Three (3) of the 22 subjects did not have any αvβ3 integrin results. Ki-inp-Patlak is a graphical analysis technique based on the compartment model that uses linear regression to identify and analyze pharmacokinetics of tracers involving irreversible uptake.

  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]

    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively.

    The Logan plot is the counterpart of the Patlak plot for reversible radiotracers.

  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between SUVw_55 and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]

    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively.

    SUVw_55 is the standard uptake value at 55 minutes post-injection, normalized to weight.

  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]

    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.

    Twelve (12) of the 22 subjects had renal cell carcinoma (RCC) the remaining subjects did not have RCC.

    SUVR_55_blood is the standard uptake value ratio (tumor-to-blood) at 55 minutes post-injection.

  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 Integrin Expression in Tumors. (Correlation Between SUVw_55 and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and αvβ3 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
To correlate the magnitude of [18F]AH-111585 uptake and retention with quantitative measurement of the levels of ανβ3 integrin expression in tumours. [ Time Frame: Dynamic PET & Static PET immediately after administration of agent in succession; Tissue sample acquisition within 2 weeks of PET imaging. IHC of ανβ3 integrin in an ongoing manner upon receipt at TMD. ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00565721 on ClinicalTrials.gov Archive Site
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]

    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. 0.60 to 0.44 equals a moderately positive correlation and 0.33 to 0.37 equals a weak positive correlation.

    Two (2) of the 22 subjects did not have any αvβ5 integrin results.

  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between SUVw_55 and αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between SUVw_55 and αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
  • Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ5 Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and αvβ5 Optical Density) [ Time Frame: Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. ] [ Designated as safety issue: No ]
    Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
  • To correlate tumour perfusion and vascular permeability in tumour tissue (as measured by dynamic contrast enhanced computed tomography [DCE-CT]) with the magnitude of uptake and retention of [18F]AH-111585. [ Time Frame: Tissue sample acquisition within 2 weeks of PET imaging IHC of Oncology & angiogenic biomarkers in an ongoing manner upon receipt at TMD. DCE-CT within 2 weeks of PET and prior to tissue sample. ] [ Designated as safety issue: No ]
  • To correlate [18F]AH-111585 accumulation in tumours obtained from PET images to the expression of VEGF; VEGFr; AKT and p-AKT; MAPK and p-MAPK; and MVD in tumours by means of immunohistologic analysis of tumour tissue samples. [ Time Frame: Tissue sample acquisition within 2 weeks of PET imaging IHC of Oncology & angiogenic biomarkers in an ongoing manner upon receipt at TMD. ] [ Designated as safety issue: No ]
  • To obtain preliminary data on the feasibility of detection of both primary and metastatic tumour lesions in particular tumour types using [18F]AH-111585 PET as compared to standard of care modalities. [ Time Frame: Dynamic PET & Static PET immediately after administration of agent in succession ] [ Designated as safety issue: No ]
  • To assess the safety of a single intravenous administration of a maximum activity of 375 MBq [18F]AH-111585 in subjects with solid tumours. [ Time Frame: All blood samples at assigned time-points throughout the schedule of events. Serum samples at baseline, + 3 weeks and +6 weeks from PET imaging. ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging

This proof-of-concept study is designed to assess the ability of [18F]AH-111585 PET imaging to detect tumors and angiogenesis. Up to 30 evaluable subjects are planned to be included at up to 2 study centers in the US. Subjects are considered evaluable if they undergo administration of AH-111585 (18F) Injection, dynamic and static PET imaging, and tumor tissue acquisition. The targeted population is adult subjects at initial diagnosis or recurrence with tumors ≥2.5 cm in diameter who are scheduled to undergo resection or biopsy of the tumor as a result of routine clinical treatment. The tumors must belong to one of the following 5 types:

  • High-grade glioma, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma
  • Lung cancer, including small cell lung cancer and non-small cell lung cancer
  • Head and neck (H&N) tumors, including laryngeal squamous cell carcinoma, well-differentiated thyroid and oral cavity carcinoma
  • Sarcoma
  • Melanoma

Safety will be assessed from the rates of adverse events, changes in vital signs, changes in electrocardiogram (ECG) parameters, changes in physical examination findings, and changes in clinical laboratory findings.

Efficacy will be assessed as the correlations between parameters derived from the PET images and the reference standards. The reference standards will be immunohistology for αvβ3 integrins and other biomarkers specific for oncology and angiogenesis and from the standard of care imaging.

Measures obtained from optional DCE-CT imaging may also be used to compare the uptake and retention of [18F]AH-111585 in tumors obtained from the dynamic PET to assess functional status of the vascular system of the tumor.

Not Provided
Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • High-grade Glioma
  • Lung Cancer
  • Head & Neck Cancer
  • Sarcoma
  • Melanoma
Drug: Fluciclatide Injection - (AH111585 (F18))
18F labelled Cyclic RGD peptide PET agent for injection.
Other Name: Fluciclatide
Experimental: Fluciclatide Injection - (AH111585 (F18))
Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
Intervention: Drug: Fluciclatide Injection - (AH111585 (F18))
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
September 2012
October 2011   (final data collection date for primary outcome measure)

Selection of Subjects: The targeted subject population is adult subjects at initial diagnosis or recurrence with tumours ≥2.5 cm in diameter who are scheduled to undergo resection or biopsy of the tumour as a result of routine clinical treatment.

General Inclusion Criteria for all Subjects:

  • The subject is ≥18 years old.
  • The subject has been diagnostically imaged and is suspected of having a primary or metastatic tumour lesion ≥2.5 cm of one of the following types: high-grade glioma, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, including small cell lung cancer and non-small cell lung cancer; H&N tumours, including laryngeal squamous cell carcinoma, and well-differentiated thyroid and oral cavity carcinoma; sarcoma; and melanoma.
  • The subject is scheduled to undergo resection or biopsy of the ≥2.5 cm target tumour as a result of routine clinical treatment.
  • The subject is scheduled to undergo or has received standard of care diagnostic imaging work-up (following the study centre's routine procedures), e.g. CT with or without contrast, MRI with or without contrast, bone scintigraphy, X-ray, or FDG-PET.
  • Female subjects need to be either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post menopausal (cessation of menses for more than 1 year), or if of childbearing potential the results of a serum pregnancy test performed within 24 hours must be negative and with the result known before administration of AH-111585 (18F) Injection. Female subjects of reproductive potential should also employ an effective method of birth control. Barrier contraceptives must be used throughout the study in both sexes.
  • The subject is able and willing to comply with study procedures, and signed and dated informed consent is obtained.
  • The subject has a blood urea nitrogen value and serum creatinine value of ≤1.5 of the upper normal limit.
  • The subject has a platelet count of >75,000 x 10^6/L.
  • The subject has a haemoglobin value of >9 g/dL.
  • The subject has a prothrombin time and an activated partial thromboplastin time and within normal limits.
  • The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care, i.e. Eastern Cooperative Oncology Group performance status is 0 to 2, such that the subject has a high chance to complete the study.
  • The subject has not received any anti-angiogenic agents (e.g. bevacizumab, sorafenib, sunitinib) within 10 days prior to PET imaging.
  • The subject has had no open wounds within 10 days prior to study entry.
  • The chosen target tumour is not within the liver.

Inclusion Criteria Specific for Subjects with High-grade Glioma:

  • The subject is suspected of having supratentorial malignant primary glioma (by biopsy or presenting MRI characteristics as determined by the subject's clinician) requiring further surgical resection as part of the recommended treatment plan for their newly diagnosed disease. These gliomas include glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma.
  • The subject has undergone recent biopsy of newly diagnosed high-grade glioma, has recovered from the effects of surgical biopsy, and baseline on-study MRI/CT is performed within 14 days of entry into the study.

Exclusion Criteria:

  • The subject is lactating.
  • The subject is being treated with heparin or coumadin.
  • The subject has received another investigational medicinal product (IMP) within 14 days before, or will receive an IMP within 1 week after administration of AH-111585 (18F) Injection.
  • The subject was previously included in this study.
  • The subject experienced substantial changes in their medical status before all essential study procedures (including all imaging procedures and surgical excision or biopsy) are performed.
  • The subject has any contraindication to any of the study procedures, products used or its constituents (e.g. X-ray contrast media).
  • The subject has known hyper- or hypo-coagulation syndromes. Such coagulopathies include but are not limited to Von Willebrand disease, Protein C deficiency, Protein S deficiency, Hemophilia A/B/C, Factor-V Leiden, and Bernard-Soulier syndrome.
  • The subject is unable to lie down for 125 minutes.
  • The subject suffers from claustrophobia.
  • The subject has known diagnosis of human immunodeficiency virus (HIV) infection.
  • The subject has known diagnosis of hepatitis B or C infection.
  • The subject has known diagnosis of mental incapacitation and it affects their ability to consent.
  • The subject has been diagnosed with a primary or metastatic tumour lesion <2.5 cm.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00565721
GE-135-003
No
GE Healthcare
GE Healthcare
Not Provided
Study Director: Jeffrey Winick, Ph.D. GE Healthcare
GE Healthcare
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP